Newswise — With increasing focus on genomic medicine and preventative healthcare, investors are grappling with the challenge of commercial models that can make preventative therapies viable.
Dr. Jarod Rutledge, Biomarkers Lead at the Amaranth Foundation, highlights the need to shift from treating disease to restoring youthful health—an approach that could make longevity-focused medicine commercially feasible.
"I think if you're trying to do genomic management, or something that's purely preventative, commercial models are very challenging. But if you can start from a state of disease and walk all the way back to a state of youthful health, then I think that is really promising."
Would you be interested in learning more about how investment strategies can support scalable longevity solutions?
RSS